Eli Lilly (LLY) has been in the spotlight recently with various events impacting its market performance. Criticism by RFK Jr., an obesity-drug critic and the Trump-appointed head of the U.S Department of Health and Human Services has caused concerns. Despite this, some consider it an attractive opportunity, particularly on a price drop. The stock fell more than 10% in a month, yet call volume is above normal and directionally bullish. This indicates investors anticipate an upward movement. Lilly has started legal proceedings against the government over the 340B drug-discount program, adding further volatility. The results from the
Phase 3 SURMOUNT-1 three-year study have been announced, although details aren’t provided. Lilly’s Q3 performance was below estimates and led to a reduction in profit guidance, inducing a stock tumble. The good news is that around
99% of patients using Lilly's weight-loss drug remained diabetes-free. Investors are curious about the potential investment opportunities with LLY, especially given its
innovative edge in the pharmaceutical industry.
Eli Lilly LLY News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Fri, 15 Nov 2024 18:14:49 GMT -
Rating 3
- Innovation 7
- Information 5
- Rumor -4
